Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

2005526 citationsJournal Article

Authors

Frank A. Scappaticci

Louis Fehrenbacher · Kaiser Permanente Vallejo Medical Center

Thomas H. Cartwright · The US Oncology Network

John D. Hainsworth · Sarah Cannon

W. Heim · Hematology and Oncology Associates of Northeastern Pennsylvania

Jordan Berlin · Vanderbilt University Medical Center

Fairooz F. Kabbinavar · University of California, Los Angeles

Abstract

Bevacizumab administered in combination with 5-fluorouracil/leucovorin-based chemotherapy 28-60 days after primary cancer surgery caused no increased risk of wound healing complications compared with chemotherapy alone. While wound healing complications were increased in patients who had major surgery during bevacizumab therapy, the majority of bevacizumab-treated patients experienced no complications.

Topics & Keywords

Colorectal Cancer Treatments and Studies Cancer Treatment and Pharmacology Colorectal Cancer Surgical Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Surgical Oncology

Volume 91, Issue 3, pp. 173-180

DOI: 10.1002/jso.20301

Field-Weighted Citation Impact: 19.67